PROJECT 5 Successful transition from the laboratory to manufacture is an essential step in the development of a topical non-vaccine biomedical prevention (nBP) candiadate. For intravaginal rings (IVRs) delivering antiretroviral (ARV) drugs, the timeline for this process can be as long as, or longer than, the initial development, and be much more expensive. The overarching goal of this IPCP-MBP effort is to develop IVR formulations of multiple ARV combinations for prevention of sexual HIV transmission, emphasizing the needs of women in the developing world. The specific objectives of Project 5 are to establish GMP manufacturing capability to advance the best-performing combination ARV IVR identified through Project 1 (pharmacokinetics), Project 2 (safety), Project 3 (efficacy), and Project 4 (pre-Phase I clinical trial) efforts into post-IPCP Phase 1 clinical trials. Our overall pod-IVR manufacturing strategy is to apply a combination of established pharmaceutical manufacturing techniques to a novel production process, already validated with NIH R44 funding for a single- ARV IVR, minimizing both the cost and timeline for translating an efficacious ARV combination IVR to clinical trials and, ultimately, protecting women from HIV infection.
Aim 1 is to develop procedures for pre-GMP small- scale manufacture based on the formulation results from Core B. Completed manufacturing methods will be transferred to and validated in a GMP environment in Aim 2 to develop the capacity for production of clinical lots of ARV IVRs under cGMP. A clinical lot of the best-performing candidate will be manufactured and evaluated in an IND-enabling, GLP, safety study in sheep (Aim 3).
In Aim 4, an amended IND, or a new IND application depending on the final ARV IVR candidate selected by the IPCP, will be prepared and submitted to the FDA, in collaboration with Core A, in anticipation of future Phase 1 clinical trials. Upon completion of this Project, the capability and capacity to provide ARV pod-IVRs manufactured under cGMP to the IND-enabling GLP toxicology study and post-IPCP clinical trials will be achieved. The manufacturing capacity established in the IPCP-MBP will enable the transition of the final selected combination IVR into clinical trial and allow other nBP strategies based on the pod-IVR to be rapidly advanced in the future.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Oak Crest Institute of Science
United States
Zip Code
Guthrie, Kate M; Rosen, Rochelle K; Vargas, Sara E et al. (2018) User evaluations offer promise for pod-intravaginal ring as a drug delivery platform: A mixed methods study of acceptability and use experiences. PLoS One 13:e0197269
Vincent, Kathleen Listiak; Moss, John A; Marzinke, Mark A et al. (2018) Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc. PLoS One 13:e0201952
Medina-Colorado, Audrie A; Vincent, Kathleen L; Miller, Aaron L et al. (2017) Vaginal ecosystem modeling of growth patterns of anaerobic bacteria in microaerophilic conditions. Anaerobe 45:10-18
Gallay, Philippe A; Chatterji, Udayan; Kirchhoff, Aaron et al. (2017) Prevention of vaginal and rectal HIV transmission by antiretroviral combinations in humanized mice. PLoS One 12:e0184303
Churchman, Scott A; Moss, John A; Baum, Marc M (2016) Accurate measurement of female genital tract fluid dilution in cervicovaginal lavage samples. J Chromatogr B Analyt Technol Biomed Life Sci 1017-1018:75-81
Blaser, Martin J; Cardon, Zoe G; Cho, Mildred K et al. (2016) Toward a Predictive Understanding of Earth's Microbiomes to Address 21st Century Challenges. MBio 7:
Moss, John A; Butkyavichene, Irina; Churchman, Scott A et al. (2016) Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. Antimicrob Agents Chemother 60:3759-66
Baum, Marc M; Butkyavichene, Irina; Churchman, Scott A et al. (2015) An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate. Int J Pharm 495:579-587